Molecular Pharmacology Financials
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular |
Molecular Pharmacology Stock Summary
Molecular Pharmacology competes with Vertex Pharmaceuticals, BioNTech, Moderna, Regeneron Pharmaceuticals, and Viking Therapeutics. Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. Molecular Pharmacology is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Drug Discovery Centre, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.mpl-usa.com |
| Phone | 61 8 9443 3011 |
| Currency | USD - US Dollar |
Molecular Pharmacology Key Financial Ratios
Molecular Pharmacology's financial ratios allow both analysts and investors to convert raw data from Molecular Pharmacology's financial statements into concise, actionable information that can be used to evaluate the performance of Molecular Pharmacology over time and compare it to other companies across industries.| Return On Asset | -5.69 | |||
| Beta | 42.97 |
Molecular Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Pharmacology's current stock value. Our valuation model uses many indicators to compare Molecular Pharmacology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Pharmacology competition to find correlations between indicators driving Molecular Pharmacology's intrinsic value. More Info.Molecular Pharmacology is rated below average in return on asset category among its peers. It also is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Molecular Pharmacology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Molecular Pharmacology's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Molecular Pharmacology Systematic Risk
Molecular Pharmacology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Molecular Pharmacology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Molecular Pharmacology correlated with the market. If Beta is less than 0 Molecular Pharmacology generally moves in the opposite direction as compared to the market. If Molecular Pharmacology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Molecular Pharmacology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Molecular Pharmacology is generally in the same direction as the market. If Beta > 1 Molecular Pharmacology moves generally in the same direction as, but more than the movement of the benchmark.
Complementary Tools for Molecular Pink Sheet analysis
When running Molecular Pharmacology's price analysis, check to measure Molecular Pharmacology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Pharmacology is operating at the current time. Most of Molecular Pharmacology's value examination focuses on studying past and present price action to predict the probability of Molecular Pharmacology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Pharmacology's price. Additionally, you may evaluate how the addition of Molecular Pharmacology to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |